Lamotrigine - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for lamotrigine and what is the scope of freedom to operate?
Lamotrigine
is the generic ingredient in five branded drugs marketed by Glaxosmithkline Llc, Actavis Elizabeth, Amneal Pharms, Dr Reddys Labs Ltd, Endo Operations, Rubicon, Torrent, Wockhardt Bio Ag, Yiling, Zydus Pharms, Alembic, Aurobindo Pharma, Glenmark Pharms Ltd, Jubilant Generics, Norvium Bioscience, Sandoz, Taro, Teva, Watson Labs, Zydus Pharms Usa Inc, Ajanta Pharma Ltd, Amring Pharms, Impax Labs Inc, Sciegen Pharms Inc, Actavis Totowa, Alembic Pharms Ltd, Alkem Labs Ltd, Chartwell Molecular, Granules, Hikma Pharms, Jubilant Cadista, Lupin Ltd, Natco Pharma, Rising, Roxane, Taro Pharm Inds, Torrent Pharms, Unichem Labs Ltd, Zennova, and Zydus Pharms Usa, and is included in fifty-three NDAs. There is one patent protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.Lamotrigine has forty-four patent family members in thirty countries.
There are thirty-two drug master file entries for lamotrigine. Fifty-three suppliers are listed for this compound. There are three tentative approvals for this compound.
Summary for lamotrigine
International Patents: | 44 |
US Patents: | 1 |
Tradenames: | 5 |
Applicants: | 40 |
NDAs: | 53 |
Drug Master File Entries: | 32 |
Finished Product Suppliers / Packagers: | 53 |
Raw Ingredient (Bulk) Api Vendors: | 150 |
Clinical Trials: | 210 |
Patent Applications: | 6,918 |
Drug Prices: | Drug price trends for lamotrigine |
Drug Sales Revenues: | Drug sales revenues for lamotrigine |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for lamotrigine |
What excipients (inactive ingredients) are in lamotrigine? | lamotrigine excipients list |
DailyMed Link: | lamotrigine at DailyMed |
Recent Clinical Trials for lamotrigine
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Mental Health Services in the Capital Region, Denmark | Phase 4 |
Westfälische Wilhelms-Universität Münster | Phase 4 |
Dr. Inge Winter | Phase 4 |
Generic filers with tentative approvals for LAMOTRIGINE
Applicant | Application No. | Strength | Dosage Form |
⤷ Sign Up | ⤷ Sign Up | 200MG | TABLET;ORAL |
⤷ Sign Up | ⤷ Sign Up | 150MG | TABLET;ORAL |
⤷ Sign Up | ⤷ Sign Up | 100MG | TABLET;ORAL |
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for lamotrigine
Drug Class | Anti-epileptic Agent Mood Stabilizer |
Mechanism of Action | Dihydrofolate Reductase Inhibitors Organic Cation Transporter 2 Inhibitors |
Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
Anatomical Therapeutic Chemical (ATC) Classes for lamotrigine
Paragraph IV (Patent) Challenges for LAMOTRIGINE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
LAMICTAL XR | Extended-release Tablets | lamotrigine | 25 mg, 50 mg, 100 mg, 200 mg, 250 mg, and 300 mg | 022115 | 1 | 2014-02-12 |
LAMICTAL ODT | Orally Disintegrating Tablets | lamotrigine | 25 mg, 50 mg, 100 mg, and 200 mg | 022251 | 1 | 2009-12-21 |
US Patents and Regulatory Information for lamotrigine
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Rubicon | LAMOTRIGINE | lamotrigine | TABLET;ORAL | 078625-001 | Jan 27, 2009 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Taro Pharm Inds | LAMOTRIGINE | lamotrigine | TABLET;ORAL | 078525-002 | Jan 27, 2009 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Unichem Labs Ltd | LAMOTRIGINE | lamotrigine | TABLET;ORAL | 090170-002 | Oct 6, 2011 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Rising | LAMOTRIGINE | lamotrigine | TABLET;ORAL | 077420-003 | Jan 27, 2009 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Alembic Pharms Ltd | LAMOTRIGINE | lamotrigine | TABLET;ORAL | 090607-001 | Jan 13, 2011 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for lamotrigine
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Glaxosmithkline Llc | LAMICTAL XR | lamotrigine | TABLET, EXTENDED RELEASE;ORAL | 022115-004 | May 29, 2009 | ⤷ Sign Up | ⤷ Sign Up |
Glaxosmithkline Llc | LAMICTAL CD | lamotrigine | TABLET, FOR SUSPENSION;ORAL | 020764-002 | Aug 24, 1998 | ⤷ Sign Up | ⤷ Sign Up |
Glaxosmithkline Llc | LAMICTAL XR | lamotrigine | TABLET, EXTENDED RELEASE;ORAL | 022115-001 | May 29, 2009 | ⤷ Sign Up | ⤷ Sign Up |
Glaxosmithkline Llc | LAMICTAL | lamotrigine | TABLET;ORAL | 020241-002 | Dec 27, 1994 | ⤷ Sign Up | ⤷ Sign Up |
Glaxosmithkline Llc | LAMICTAL | lamotrigine | TABLET;ORAL | 020241-005 | Dec 27, 1994 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for lamotrigine
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Cyprus | 1109119 | ⤷ Sign Up | |
Denmark | 1524981 | ⤷ Sign Up | |
Morocco | 27509 | FORMULATIONS A LIBERATION PROLONGEE CONTENANT DE LA LAMOTRIGINE | ⤷ Sign Up |
Norway | 334221 | ⤷ Sign Up | |
Hong Kong | 1077003 | SUSTAINED RELEASE FORMULATIONS COMPRISING LAMOTRIGINE | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.